Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07032220

Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study

In this study, following the full informed consent of patients regarding the safety and potential benefits of the new intervention regimen, pathologically confirmed lymph nodes were pre-labeled with carbon nanoparticles prior to neoadjuvant chemotherapy. This was done to investigate the detection rate of carbon nanoparticle-labeled lymph nodes and to assess the stability and safety of carbon nanoparticles. Additionally, the dye single tracer method was employed for sentinel lymph node biopsy to evaluate the false-negative rate of TAD. This is an open-label, single-arm, multi-center prospective clinical trial. The primary objectives of this study are to evaluate the accuracy, feasibility, and safety of this method, thereby improving the quality of life and reducing postoperative complications for breast cancer patients while ensuring treatment efficacy.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Breast Cancer Surgery Neoadjuvant Therapy Sentinel Lymph Node Biopsy (SLNB)

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Study Officials

Fuzhou, Fujian, 350001, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women aged 18-70 years
  • The primary breast lesion was confirmed as invasive breast cancer by core needle biopsy
  • Axillary lymph node metastasis confirmed by fine needle aspiration or core needle biopsy
  • plan to undergo neoadjuvant chemotherapy
  • operable breast cancer
  • Patients with good heart, lung, liver, and kidney function are suitable for surgery
  • Informed consent

Exclusion criteria

  • Surgery is not planned or impossible
  • Metastasis of supraclavicular lymph nodes
  • distant metastasis, excluding bone metastasis
  • previous ipsilateral axillary surgery or radiotherapy
  • Due to personal or family factors, the patient is unable to cooperate with the surgical treatment recommended by the doctor according to the condition (breast conserving surgery or radical surgery).
  • Patients with severe heart and lung diseases, uncontrolled infectious diseases and other non-tumor related diseases could not tolerate comprehensive treatment such as surgery and chemotherapy
  • Unable to sign the informed consent form due to mental illness or other reasons
  • Poor medical compliance, and the study group believed that the patients could not complete the trial treatment process and follow-up according to the standard

Treatment and study plan

carbon suspension

Drug

Before primary systemic therapy, a core needle biopsy or fine-needle aspiration of the most suspicious axillary lymph node was performed.22 Sterile black carbon suspension (0.5 mL: 25 mg, Chongqing LUMMY Pharmaceutical Co) was injected in the cortex of the metastatic node under ultrasound guidance using a 25G needle by a trained ultrasonographer at the time of biopsy or during a separate session. The injection volume was recorded and varied depending on node size and operator. The trained ultrasonographer had more than 5 years of puncture experience. Of note, for the patients with multiple abnormal nodes or N3 disease under ultrasound at diagnosis, only the pathologically-proven lymph node is marked with carbon suspension.

Primary outcomes

  1. By analyzing the detection rate of TAD, FNR and NPV, the feasibility and accuracy of this method in evaluating axillary lymph nodes of breast cancer patients after neoadjuvant therapy were evaluated.

    Time frame: 24 months

Secondary outcomes

  1. The feasibility and accuracy of TLNB and SLNB in axillary lymph node evaluation were evaluated by analyzing the detection rate of TLNB and SLNB, FNR and NPV.

    Time frame: 24 months

Other outcomes

  1. Evaluate the safety of carbon nanoparticles in breast cancer lymph node labeling

    Time frame: 24 months

Sponsors and collaborators

Lead sponsor

Fujian Medical University Union Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Jun 22, 2025
Registry last updated
Jun 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.